Seagen Inc (SGEN) Company Profile & Statistics

Seagen Inc
SGEN
(Nasdaq - US)
Closed
197.65
-0.45 (-0.23%)
in:usd•As of: Mar 24, 2023 15:59 UTC -4
After Market:197.6-0.05 (-0.03%)
Open
198.10
High
198.30
Low
196.93

About Seagen Inc

CEO

David R. Epstein

Headquarters

21823 30th drive se, suite

bothell, wa 98021, united states

Auditor

PricewaterhouseCoopers

Employees

3,256

Share Holders

Website

http://www.seagen.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.

Seagen Inc Statistics

Valuation Measures

Market Capitalization ²	36.92B
Enterprise Value	36.60B
Enterprise Value/EBITDA (ttm)	-68.04
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	13.12
Price to Sales (ttm)	18.86
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	79.11%
Operating Margin (ttm)	-31.10%
Profit Margin (ttm)	-31.14%
Return on Equity (ttm)	-21.13%
Return on Invested Capital (ttm)	-21.20%
Return on Assets (ttm)	-16.79%

Income Statement

Revenue (ttm)	1.96B
Revenue Per Share (ttm)	10.51
Gross Profit (ttm)	1.55B
EBITDA (ttm)³	-537.88M
Net Income Avi to Common (ttm)	-610.31M
Diluted EPS (ttm)	-3.30

Share Statistics

Beta (5Y Monthly)	0.53
52-Week Change	39.91%
S&P500 52-Week Change	-12.15%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	186.79M
Dividend Yield	0.00%
Float ⁴	135.80M
% Held by Insiders	27.30%
% Held by Institutions	86.25%

Balance Sheet

Total Cash (mrq)	1.74B
Total Cash Per Share (mrq)	9.29
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	3.42%
Quick Ratio (mrq)	2.90%
Book Value Per Share (mrq)	15.03

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.46
Free Cash Flow (ytd)	-531.09M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Seagen Inc

Trade With A Regulated Broker